We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+19.3%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.75B
AUM Growth
+$73.2M
(+4.4%)
Cap. Flow
-$158M
Cap. Flow
% of AUM
-9.02%
Top 10 Holdings %
Top 10 Hldgs %
69.04%
Holding
38
New
9
Increased
6
Reduced
9
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$74.2M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
+$66.5M |
| 3 |
Viatris
VTRS
|
+$52M |
| 4 |
Coherus Oncology
CHRS
|
+$37.2M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$32.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$91.4M |
| 2 |
Ventas
VTR
|
+$87.1M |
| 3 |
HCA Healthcare
HCA
|
+$76.4M |
| 4 |
Biogen
BIIB
|
+$63.3M |
| 5 |
Tenet Healthcare
THC
|
+$50.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.98% |
| 2 | Technology | 10.19% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHNG
1
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $178M | 10.19% |
15,900,000
+2,900,000
| +22% | +$32.6M |
|
|
2
Viatris
VTRS
$20.7B
| $177M | 10.12% |
11,000,000
+3,205,000
| +41% | +$52M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
| $157M | 8.99% |
1,400,000
-250,000
| -15% | -$26.5M |
|
4
Alkermes
ALKS
$8.39B
| $141M | 8.05% |
7,250,000
+1,200,000
| +20% | +$19.5M |
|
5
Perrigo
PRGO
$1.43B
| $124M | 7.11% |
2,250,000
+250,000
| +13% | +$13.2M |
|
6
GSK
GSK
$104B
| $122M | 7% |
2,400,000
| – | – |
|
7
Universal Health Services
UHS
$9.88B
| $92.9M | 5.31% |
1,000,000
-125,000
| -11% | -$12.5M |
|
|
BLUE
8
DELISTED
bluebird bio
BLUE
| $77.8M | 4.45% |
+98,430
| New | +$74.2M |
|
9
Nektar Therapeutics
NKTR
$2.41B
| $69.5M | 3.98% |
200,000
| – | – |
|
|
10
Ironwood Pharmaceuticals
IRWD
$614M
| $67.1M | 3.84% |
+6,500,000
| New | +$66.5M |
|
11
Sarepta Therapeutics
SRPT
$1.64B
| $64.1M | 3.67% |
400,000
-325,000
| -45% | -$44.2M |
|
12
Ascendis Pharma A/S
ASND
$16.5B
| $51.8M | 2.96% |
350,000
-186,710
| -35% | -$25.6M |
|
13
Myriad Genetics
MYGN
$507M
| $45.4M | 2.6% |
4,000,000
+1,650,000
| +70% | +$23.4M |
|
14
Brookdale Senior Living
BKD
$3.49B
| $44.3M | 2.53% |
15,000,000
-2,000,000
| -12% | -$6.47M |
|
|
15
Coherus Oncology
CHRS
$227M
| $39.3M | 2.25% |
+2,200,000
| New | +$37.2M |
|
16
Collegium Pharmaceutical
COLL
$1.17B
| $35M | 2% |
2,000,000
| – | – |
|
|
AMAG
17
DELISTED
AMAG Pharmaceuticals
AMAG
| $33.6M | 1.92% |
4,390,000
| – | – |
|
18
Glaukos
GKOS
$9.9B
| $28M | 1.6% |
+730,000
| New | +$27.2M |
|
19
Puma Biotechnology
PBYI
$402M
| $25M | 1.43% |
2,400,000
+450,000
| +23% | +$4.66M |
|
20
Teva Pharmaceuticals
TEVA
$41.2B
| $24.7M | 1.41% |
+2,000,000
| New | +$22.6M |
|
|
TECX
21
Tectonic Therapeutic
TECX
$538M
| $23.6M | 1.35% |
112,500
| – | – |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $21.8M | 1.25% |
+525,000
| New | +$19.1M |
|
23
Atara Biotherapeutics
ATRA
$73.6M
| $20.4M | 1.17% |
56,000
-3,150
| -5% | -$796K |
|
24
Immunovant
IMVT
$8.11B
| $19.5M | 1.11% |
+800,000
| New | +$17.1M |
|
|
TBIO
25
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $17.9M | 1.03% |
1,000,000
-765,000
| -43% | -$11.5M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Camber Capital Management held 38 positions worth $1.75B, up 4.4% from $1.67B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Camber Capital Management withdrew a net $158M in Q2 2020, closing 8 positions and reducing 9 holdings. Its most notable exit was AbbVie, an estimated $91.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 85% a quarter earlier, followed by Technology and Real Estate.
Against the trend, Camber Capital Management opened a new position in bluebird bio worth $77.8M.
- Camber Capital Management's largest Q2 2020 buy was bluebird bio: 98,430 shares worth $77.8M.
- Camber Capital Management added most to Viatris in Q2 2020, an estimated $52M increase.
- Camber Capital Management's biggest Q2 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $49.4M.
- Camber Capital Management fully exited AbbVie in Q2 2020, selling an estimated $91.4M.
- Camber Capital Management's ten largest holdings make up 69% of its $1.75B portfolio in Q2 2020.
- Camber Capital Management opened 9 new positions and closed 8 in Q2 2020.
- Camber Capital Management's portfolio value rose 4.4% quarter-over-quarter to $1.75B.
Based on Camber Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.